You are here
EYDIS BIO, INC.
# of Employees: 3
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Improving the Oral Bioavailability and In vivo Efficacy of a Novel TAK1 Inhibitor Targeting Rheumatoid ArthritisAmount: $223,898.00
Project SummaryAbstract Rheumatoid arthritisRAis a chronic inflammatory disease in which hyperactivated immune cells induce maladaptive persistent inflammation in the jointsleading to synovial inflamm ...STTRPhase I2019Department of Health and Human Services National Institutes of Health